Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BIAF with free AI briefings, catalyst countdowns, and dilution alerts.
Start 7-day free trial → Log in

BIAF · bioAffinity Technologies, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.4M Cash, Jun 2026
2mo Cash Runway (est.)
-72% Share Count, 1 Year
Follow BIAF by email Get an email when BIAF pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BIAF, unsubscribe in one click. Privacy

💰 Cash Runway & Dilution Risk

BIAF reported $2.4M in cash and short-term investments (as of Jun 30, 2026) and used about $3.2M/quarter in operations, an estimated runway of 2.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIAF files for a raise →

Get the full BIAF picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIAF and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.